European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update

Babjuk, Marko; Burger, Maximilian; Compérat, Éva; Gontero, Paolo; Mostafid, Hugh; Palou, Joan; Rhijn, Bas W.G. van; Rouprêt, Morgan; Shariat, Shahrokh F.; Sylvester, Richard; Zigeuner, Richard; Čapoun, Otakar; Cohen, Daniel L.; Escrig, J.L. Domínguez; Hernández, Virginia; Peyronnet, B.; Seisen, Thomas; Soukup, Viktor

doi:10.1016/j.eururo.2019.08.016

Cited by 1,108 publications

(1,357 citation statements)

References 135 publications

Supporting

Mentioning

1,214

Contrasting

Unclassified

Order By: Relevance

“…-In case of small bladder tumors, consider a single-dose intravesical chemotherapy within 24 hours of TURBT (not immunotherapy). The most commonly used agents are: mitomycin and gemcitabine, in Brazil just gemcitabine isavaiable (16).…”

Section: Intravesical Instillationmentioning

confidence: 99%

“…In selected cases we can consider postpone one dose during the maintenance. In the case of BCG shortage supply, gemcitabine can be used (16,17).…”

Section: Intravesical Instillationmentioning

confidence: 99%

“…In general, TURBT should be performed whenever possible. It is important to highlight that we recommend performing a cold-cup biopsy of the base of the lesion to ensure representation of the detrusor muscle and avoid the need for repeat TURBT due to undersampling (16).…”

Section: Non-invasive Bladder Neoplasmmentioning

confidence: 99%

See 2 more Smart Citations

Impact of the COVID-19 Pandemic on the Urologist’s clinical practice in Brazil: a management guideline proposal for low- and middle-income countries during the crisis period

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Intravesical Instillationmentioning

confidence: 99%

“…In selected cases we can consider postpone one dose during the maintenance. In the case of BCG shortage supply, gemcitabine can be used (16,17).…”

Section: Intravesical Instillationmentioning

confidence: 99%

See 1 more Smart Citation

Impact of the COVID-19 Pandemic on the Urologist’s clinical practice in Brazil: a management guideline proposal for low- and middle-income countries during the crisis period

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Local BCG chemo instillation has been widely used in uro-oncologic practice since 1976 [14]. Current Guidelines recommend the use of BCG instillation for treatment of non-muscle invasive bladder cancer (T1 high grade) or carcinoma in situ (CIS), to prevent progression and postpone radical surgical intervention [15]. The exact mechanism of the anti-tumor effect of local BCG instillation is not fully understood, but available data suggest that T H1 -mediated immune reaction plays a crucial role in the procedure.…”

Section: Covid-19 and Bcgmentioning

confidence: 99%

COVID-19 research: promising tracks leading to uro-oncology

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Patients were followed by voided urine cytology, by the Bladder EpiCheck test, and by white-light cystoscopy, according to the current European Association of Urology guidelines. 9 We reserved photodynamic cystoscopy for patients with positive cytology and no visible bladder tumor; in our series, none of our patients underwent photodynamic cystoscopy in an outpatient setting.…”

Section: Methodsmentioning

confidence: 99%

Diagnostic predictive value of the Bladder EpiCheck test in the follow‐up of patients with non–muscle‐invasive bladder cancer

Trenti

D’Elia

Mian

et al. 2019

Cancer Cytopathology

View full text Add to dashboard Cite

Background The objective of this study was to evaluate the diagnostic accuracy of the Bladder EpiCheck test in the follow‐up of patients with non–muscle‐invasive bladder cancer (NMIBC) and to compare it with the accuracy of urinary cytology, cystoscopy, and/or histology. Methods In total, 243 patients were enrolled in the current study. Patients were evaluated by voided urine cytology, by the Bladder EpiCheck test, and by white‐light cystoscopy. Results Overall sensitivity was 33.3% for cytology, 62.3% for Bladder EpiCheck, and 66.7% for the 2 tests combined. The sensitivity of cytology increased from 7.7% in low‐grade (LG) tumors to 66.6% in high‐grade (HG) tumors; whereas, for the Bladder EpiCheck test, the sensitivity was 46.1% in LG tumors and 83.3% in HG tumors. Combined cytology and Bladder EpiCheck testing yielded an overall sensitivity of 56.4% for LG tumors and 90% for HG tumors. Overall specificity was 98.6% for cytology, 86.3% for Bladder EpiCheck, and 85.6% for the 2 tests combined. The positive predictive value was 92% for cytology and 68.2% for Bladder EpiCheck. For the 2 tests combined, it was 68.6%. The negative predictive value was similar for the 2 tests: 75.8% for cytology, 82.9% for Bladder EpiCheck, and 84.5% for the 2 tests combined. Conclusions The sensitivity of the Bladder EpiCheck test was significantly higher than that of cytology. The test performed very well in terms of specificity but could not reach the high value of cytology. The positive predictive value was higher for Bladder EpiCheck, whereas the negative predictive value was approximately the same for both tests.

show abstract

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update

Cited by 1,108 publications

References 135 publications

Impact of the COVID-19 Pandemic on the Urologist’s clinical practice in Brazil: a management guideline proposal for low- and middle-income countries during the crisis period

Impact of the COVID-19 Pandemic on the Urologist’s clinical practice in Brazil: a management guideline proposal for low- and middle-income countries during the crisis period

COVID-19 research: promising tracks leading to uro-oncology

Diagnostic predictive value of the Bladder EpiCheck test in the follow‐up of patients with non–muscle‐invasive bladder cancer

Contact Info

Product

Resources

About